(19) |
 |
|
(11) |
EP 3 945 133 A8 |
(12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
(15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
(48) |
Corrigendum issued on: |
|
12.04.2023 Bulletin 2023/15 |
(43) |
Date of publication: |
|
02.02.2022 Bulletin 2022/05 |
(22) |
Date of filing: 29.07.2020 |
|
(51) |
International Patent Classification (IPC):
|
|
(84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
(71) |
Applicant: Georg-August-Universität Göttingen Stiftung
Öffentlichen Rechts, Universitätsmedizin |
|
37075 Göttingen (DE) |
|
(72) |
Inventors: |
|
- Zimmermann, Wolfram-Hubertus
37073 Göttingen (DE)
- Tiburcy, Malte
37083 Göttingen (DE)
|
(74) |
Representative: Wichmann, Hendrik |
|
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2 81541 München 81541 München (DE) |
|
|
|
(54) |
MASS PRODUCTION OF HUMAN PLURIPOTENT STEM CELL DERIVED CARDIAC STROMAL CELL |
(57) The application describes a method for producing a population of cardiac stromal
cells from pluripotent stem cells. Specifically, the method relates to (i) inducing
epithelial-mesenchymal transition of pluripotent stem cell derived epicardial cells
and (ii) amplifying the number of cardiac stromal cells in serum-free conditions.
These cardiac stromal cells can be mass produced according to the described method
and said cells maintain the expression of CD90, CD73 and CD44 in at least 80% of the
cardiac stromal cells. Furthermore, the application relates to a population of cardiac
stromal cells, which are pluripotent stem cells derived and wherein at least 80% of
the cardiac stromal cells express CD90, CD73 and CD44. Said cardiac stromal form the
basis for several
in vitro and
in vivo applications such as the production of engineered organ tissue and the support of,
for example, heart repair. Also, a serum-free culture medium for the amplification
of cardiac stromal cells is provided herein.